Find your next paid study

Mayo ClinicNCT06911008

Diffuse Midline Glioma, H3 K27-AlteredMetastatic Malignant Neoplasm in the Central Nervous SystemRecurrent Diffuse Intrinsic Pontine Glioma+7 more

A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients With Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma

This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous s…

Children's Oncology GroupNCT04870944

Colorectal CarcinomaEndometrial CarcinomaMelanoma+19 more

A Phase 1/2 Study of Tegavivint (NSC#826393) in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come b…

Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmRefractory Malignant Solid Neoplasm+2 more

A Phase 1 Study of ZEN003694 in Combination With Binimetinib in Solid Tumors With RAS Pathway Alterations and Triple Negative Breast Cancer

This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with binimetinib in treating patients with solid tumors that carry…

National Cancer Institute (NCI)NCT05111561

~$10 – $5,625

Refractory Malignant Solid NeoplasmOsteosarcomaLeiomyosarcomas+4 more

First in Human Phase 1 Study of AOH1996 in Patients With Refractory Solid Tumors

This phase I trial studies the side effects and best dose of AOH1996 in treating patients with solid tumors that do not respond to treatment (refractory). AOH1…

City of Hope Medical CenterNCT05227326

Advanced Malignant Solid NeoplasmLocally Advanced Pancreatic CarcinomaMetastatic Pancreatic Carcinoma+6 more

Phase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors

This phase I/II trial tests the safety, side effects, and best dose of entinostat and ZEN003694 in treating patients with solid tumors that have spread to othe…

National Cancer Institute (NCI)NCT05053971

~$10 – $5,625

Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmRecurrent Malignant Solid Neoplasm+1 more

A Phase Ib/II Study of Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced Solid Tumors

This phase I/II trial tests the safety, side effects, and effectiveness of axatilimab in combination with retifanlimab and paclitaxel for the treatment of pati…

OHSU Knight Cancer InstituteNCT06320405

Advanced CholangiocarcinomaAdvanced Hepatocellular CarcinomaAdvanced Malignant Solid Neoplasm+4 more

First in Human Dose Escalation Study of AU409 in Patients With Advanced Primary Liver Cancers or Advanced Solid Tumor With Liver Predominant Metastatic Disease

This phase I trial tests the safety, side effects, and best dose of a new intervention, AU409, in treating patients with primary liver cancers that may have sp…

University of Southern CaliforniaNCT05791448

Recurrent Solid TumorRecurrent Ewing SarcomaRecurrent Hepatoblastoma+19 more

A Randomized Phase I/II Study of Talazoparib or Temozolomide in Combination With Onivyde in Children With Recurrent Solid Malignancies and Ewing Sarcoma

The phase I portion of this study is designed for children or adolescents and young adults (AYA) with a diagnosis of a solid tumor that has recurred (come back…

Advanced LymphomaAdvanced Malignant Solid NeoplasmIndolent Non-Hodgkin Lymphoma+3 more

A Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma Patients

This phase I trial studies the side effects and best dose of ubiquitin-activating enzyme (UAE) inhibitor TAK-243 (TAK-243) in treating patients with a solid tu…

National Cancer Institute (NCI)NCT06223542

~$10 – $5,625

Metastatic Malignant Solid NeoplasmMetastatic MelanomaPathologic Stage IIIC Cutaneous Melanoma AJCC v8+14 more

Phase I Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid Tumors

This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the …

DT2216 in Combination With Irinotecan for Children, Adolescents and Young Adults With Relapsed or Refractory Solid Tumors: A Phase I Study With Phase II Feasibility Cohort for Fibrolamellar Carcinoma

This phase I/II trial tests the safety, side effects and best dose of DT2216 in combination with irinotecan and how well it works in treating children, adolesc…

Childhood Fibrolamellar CarcinomaRecurrent Childhood Fibrolamellar CarcinomaRecurrent Childhood Malignant Solid Neoplasm+6 more